Cholangiocarcinoma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

51 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cholangiocarcinoma
2006-006171-20: Evaluation de l\'efficacité de la thérapie photodynamique par Photofrin sur les cholangiocarcinomes non résécables de type III ou IV

Ongoing
3
80
Europe
Photofrin 75 mg, Photofrin 15 mg, Photofrin 75 mg, Photofrin 15 mg
CHU Angers
Cholangiocarcinomes de type III ou IV (selon la classification de Bismuth), prouvé histologiquement.
 
 
2016-004448-12: A study to investigate the effects of the drug ARQ 087 in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholanciocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion. Uno studio per valutare gli effetti del farmaco ARQ 087 in pazienti che hanno un tipo di tumore al dotto biliare molto esteso o che non possono essere operati, chiamato Colangiocarcinoma Intraepatico. I pazienti sono positivi alla fusione del gene FGFR2

Ongoing
3
100
Europe
ARQ 087, ARQ 087, Capsule, hard
ARQULE INC, ArQule, Inc.
Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma Colangiocarcinoma intraepatico inoperabile o avanzato positivo alla fusione del gene FGFR2, A type of bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion Un tipo di tumore al dotto biliare che non si può operare o molto esteso, in pazienti positivi per la fusione del gene FGFR2, Diseases [C] - Cancer [C04]
 
 
BCAT, R000000983: Randamised phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resectable bile duct cancer

Completed
3
300
Japan
gemcitabine - Generic mfg.
Nagoya Surgery Support Organization, Nagoya Surgery Support Organization
Bile duct cancer
 
 
2017-004444-38: Study in Gallbladder or bile duct cancer comparing chemotherapy with gemcitabine plus cisplatin before and after radical liver resection with direct radical liver resection followed by chemotherapy or no chemotherapy (physician's decision) - A Phase III study of the German Gallbladder Cancer Registry Studie bei Gallenblasen- oder Gallengangskarzinom die Chemotherapie mit Gemcitabin plus Cisplatin vor und nach radikaler Leberresektion vergleicht mit direkter radikaler Leberresektion gefolgt von Chemotherapie oder keiner Chemotherapie (Arztentscheidung) - Eine Phase III Studie des Deutschen Gallenblasenkarzinom-Registers

Not yet recruiting
3
300
Europe
Cisplatin, Gemcitabin, Concentrate for solution for infusion, Powder for solution for infusion
Krankenhaus Nordwest gGmbH, Deutsche Forschungsgemeinschaft
incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC)), gallbladder carcinoma or biliary-tract cancer, Diseases [C] - Cancer [C04]
 
 
2018-002983-26: Phase 3 Study of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK- 3475) for First-line Therapy of Advanced Hepatocellular Carcinoma

Not yet recruiting
3
750
Europe
PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Eisai Limited., Merck Sharp & Dohme LLC, Eisai Limited, Eisai Ltd., Eisai Ltd
Advanced hepatocellular carcinoma, Advanced hepatocellular carcinoma without any prior systemic treatment, Diseases [C] - Cancer [C04]
 
 
2019-000944-82: Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable BTC

Not yet recruiting
3
1048
Europe
pembrolizumab, Keytruda (pembrolizumab, MK-3475), MK-3475, Solution for infusion, Keytruda (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder), Advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer). This study is for treatment naïve participants, Diseases [C] - Cancer [C04]
 
 
NCT03345303: Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Recruiting
3
50
RoW
Bortezomib, velcade
Zhengang Yuan
Intrahepatic Cholangiocarcinoma
12/20
12/22
AdBTC-1, NCT03779035: Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

Recruiting
3
460
RoW
Gemcitabine, Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma, Gall Bladder Carcinoma
12/20
12/23
ACTRN12615001283561: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)

Active, not recruiting
3
40
 
Australasian Gastro-Intestinal Trials Group, Australasian Gastro-Intestinal Trials Group, Cancer Australia
cholangiocarcinoma, muscle invasive gallbladder carcinoma
 
 
2019-004630-42: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Not yet recruiting
3
216
Europe
Futibatinib, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, TAS-120, Film-coated tablet, Concentrate for solution for infusion, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion
Taiho Oncology Inc, Taiho Oncology, Inc., TAIHO ONCOLOGY INC., Taiho Oncology Inc
Advanced solid tumors, Advanced solid tumors, Diseases [C] - Cancer [C04]
 
 
TOPAZ-1, NCT03875235 / 2018-004688-30: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer

Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Jul 2022 - Jul 2022: Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Jan 2022 - Jan 2022: Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Checkmark From P3 TOPAZ-1 trial for 1L BTC at ASCO-GI 2022
More
Active, not recruiting
3
810
Europe, Japan, US, RoW
Durvalumab, Placebo
AstraZeneca
Biliary Tract Neoplasms
08/21
03/25
EPIC-1511, NCT02853474: Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy

Completed
3
480
Europe
Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
Centre Oscar Lambret, Ligue contre le cancer, France, Région Nord-Pas de Calais, France, National Cancer Institute, France
Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer, Esophageal Cancer
12/21
12/22
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Recruiting
3
392
RoW
TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Cancer
03/22
02/23
PORTAL, NCT04400357: Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors

Recruiting
3
244
RoW
Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
Ruijin Hospital, Intuitive Surgical
Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis, Cholangiocarcinoma, Extrahepatic, Ampullary Adenocarcinoma, Duodenal Adenocarcinoma
10/22
11/22
KEYNOTE-966, NCT04003636: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/)

Checkmark Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Jan 2023 - Jan 2023: Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
KEYNOTE-966 China Extension study, NCT04924062: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Active, not recruiting
3
158
RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
TAICC, NCT03940378: Treatment of Advanced Intrahepatic Cholangiocarcinoma

Recruiting
3
152
RoW
Levamisole Hydrochloride, LH, Anlotinib Hydrochloride Capsules, AHC
The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Luoyang Central Hospital, Nanyang Central Hospital, Anyang Tumor Hospital, Third People's Hospital of Jiaozuo, Sanmenxia Central Hospital, pinmei Group General Hospital
ICC
02/23
02/23
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
ACTICCA-1, NCT02170090 / 2012-005078-70 / ACTRN12615001283561: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Active, not recruiting
3
789
Europe, RoW
Gemcitabine, Cisplatin, Capecitabine
Universitätsklinikum Hamburg-Eppendorf, Deutsche Krebshilfe e.V., Bonn (Germany), Cancer Research UK, Australasian Gastro-Intestinal Trials Group, Dutch Cancer Society
Cholangiocarcinoma, Gall Bladder Carcinoma
04/24
04/24
MENAC, NCT02330926 / 2013-002282-19: Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

Completed
3
221
Europe, Canada, US
standard care, nutritional supplements and advice, home-based self-assisted exercise program, Ibuprofen
Norwegian University of Science and Technology, St. Olavs Hospital, Oslo University Hospital, Cantonal Hospital of St. Gallen, Ottawa Regional Cancer Centre, Jewish General Hospital, Cross Cancer Institute, The Beatson West of Scotland Cancer Centre, Queen Margaret Hospital, Dunfermline, Cancer Research UK Edinburgh Centre, Malteser Krankenhaus Seliger Gerhardt, Tumor Biology Center Freiburg, Tumor Zentrum Aarau, Chelsea and Westminster NHS Foundation Trust, Cedars-Sinai Medical Center, Guy's and St Thomas' NHS Foundation Trust, NHS Forth Valley
Cachexia, Neoplasms
04/23
04/23
FOENIX-CCA3, NCT04093362 / 2019-004630-42: Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Active, not recruiting
3
216
Europe, Japan, US, RoW
TAS-120, Futibatinib, Cisplatin/Gemcitabine
Taiho Oncology, Inc., Taiho Oncology Inc
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
06/24
06/24
SWOG 1815, NCT03768414: Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Active, not recruiting
3
452
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel
SWOG Cancer Research Network, National Cancer Institute (NCI)
Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
10/23
07/24
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
07/24
07/24
TopDouble, NCT05924880: A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Active, not recruiting
3
116
RoW
durvalumab, IMFINZI
AstraZeneca
Biliary Tract Cancers
10/24
05/25
GAIN, NCT03673072: Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC

Recruiting
3
300
Europe
Gemcitabine, Cisplatin, Oncologically radical margin-free (R0) resection, Adjuvant chemotherapy
Krankenhaus Nordwest, German Research Foundation
Incidental Gallbladder Carcinoma, Biliary Tract Cancer
11/24
11/24
NCT04401709: Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Recruiting
3
490
RoW
Gemcitabine/Capecitabine, Capecitabine
Samsung Medical Center
Biliary Tract Cancer
03/25
03/25
NCT02773485: Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Recruiting
3
155
RoW
High Dose Radiation, Radiation, Systemic chemotherapy, Gemcitabine and Cisplatin regimen
Tata Memorial Hospital
Cholangiocarcinoma
06/25
06/25
ProvIDHe, NCT05876754: An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

Recruiting
3
220
Europe, Canada, RoW
Ivosidenib Oral Tablet
Servier Affaires Médicales
Cholangiocarcinoma
06/25
06/25
NCT04961970: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Recruiting
3
188
RoW
oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
Shi Ming
Intrahepatic Cholangiocarcinoma
07/25
07/25
TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting
3
140
Europe, Japan, US, RoW
Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen
AstraZeneca
Biliary Tract Cancer
09/25
03/26
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Not yet recruiting
3
165
RoW
TQB3454 tablets, TQB3454 tablets matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biliary Carcinoma
12/26
12/26
NCT05823311: Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Recruiting
3
80
RoW
Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin
Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Tumor Hospital of Xinjiang Medical University
Advanced Cholangiocarcinoma
12/26
12/28
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Not yet recruiting
3
480
RoW
Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma
05/27
05/27
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
FIGHT-302, NCT03656536 / 2018-002894-23: A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Checkmark From P3 FIGHT-302 trial for 1L cholangiocarcinoma at ESMO-GI 2021
Jun 2021 - Jun 2021: From P3 FIGHT-302 trial for 1L cholangiocarcinoma at ESMO-GI 2021
Checkmark First patient treated in FIGHT-302, P3 trial
Jun 2019 - Jun 2019: First patient treated in FIGHT-302, P3 trial
Recruiting
3
434
Europe, Canada, Japan, US, RoW
Pemigatinib, INCB054828, Gemcitabine, Cisplatin
Incyte Corporation
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
10/27
07/28
NCT02482454: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Active, not recruiting
3
50
RoW
Radiofrequency ablation, RFA, Cytokine-induced killer cells, CIK
The First People's Hospital of Changzhou
Cholangiocarcinoma
07/30
07/33
ChiCTR2300071465: Surufatinib plus GEMOX versus GEMOX as 1(st)-line treatment for unresectable or metastatic biliary tract cancers: a ramdomised, multicenter trial

Not yet recruiting
3
200
 
Surufatinib plus GEMOX ;GEMOX
The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, University
Biliary tract cancers
 
 
NCT04060472: Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors

Not yet recruiting
2/3
57
NA
albumin-bound paclitaxel + oxaliplatin
Dong Wang
Advanced Hepatobiliary and Malignant Tumors
04/21
10/23
DRCBD, NCT03000855: EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures

Completed
2/3
77
Europe, Japan, RoW
EUS-guided choledocho-duodenostomy, Endoscopic retrograde cholangiopancreatography with covered metallic stent
Chinese University of Hong Kong, Tokyo Medical University, Kinki University
Malignant Biliary Obstruction
12/21
12/22
SIRCCA, NCT02807181: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Completed
2/3
89
Europe, US, RoW
Cisplatin-gemcitabine, CIS-GEM, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sirtex Medical
Intrahepatic Cholangiocarcinoma
10/22
10/22
2022-001867-29: [68Ga]Ga-FAPI-46 positron emission tomography (PET) scan to improve the imaging of pancreatic and bile duct cancer. [68Ga]Ga-FAPI-46 positron emissie tomografie (PET) scan voor het beter zichtbaar maken van alvleesklier- en galwegkanker.

Ongoing
2/3
63
Europe
[68Ga]Ga-FAPI-46, V09IX, Solution for injection
Amsterdam UMC, KWF kankerbestrijding, young investigators grant (No. 11289), CCA grant (No. CCA-2-29), Cholangiocarcinoma Foundation Research Fellowship
Pancreatic carcinoma and cholangiocarcinoma Pancreascarcinoom en cholangiocarcinoom, Cancer of the pancreas and cancer of the bile duct Alvleesklierkanker en galwegkanker, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
 
 
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/22
12/24
ChiCTR2000035434: All-Trans-Retinoic Acid (ATRA) plus GEMOX vs. GEMOX alone Palliative Chemotherapy in Advanced Intrahepatic cholangiocarcinoma: A Randomized Double-Blinded Controlled Clinical Trial

Recruiting
2/3
100
 
ATRA+GEMOX ;GEMOX
Shanghai Oriental Hepatobiliary Surgical Hospital; Shanghai Oriental Hepatobiliary Surgical Hospital, Self-financing
ICC
 
 
NCT03086993 / 2016-003812-10: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Active, not recruiting
2/3
295
US
Melphalan/HDS, Melphalan/PHP, Cisplatin and Gemcitabine, Cis/Gem
Delcath Systems Inc.
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
01/23
05/23
NCT05487443: The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies

Not yet recruiting
2/3
50
RoW
Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
First People's Hospital of Hangzhou
Gemcitabine, Biliary Tract Cancer, Immune Checkpoint Inhibitors
09/23
08/24
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
FAPIChol, NCT06355427: The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma

Not yet recruiting
2/3
81
NA
[18F]F-FAPI PET-CT
Mara Veenstra, MD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), UMC Utrecht
Cholangiocarcinoma
09/27
02/28
NCT05065957: Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Recruiting
2/3
180
RoW
D07001-softgel capsules + Xeloda (or TS-1), Treatment group, mFOLFOX, Control group
InnoPharmax Inc.
Biliary Tract Cancer
07/26
12/26
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29

Download Options